NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
Final draft recommendations published on the use of nirmatrelvir plus ritonavir for COVID-19
Final draft guidance for nirmatrelvir plus ritonavir has been published by the National Institute for Health and Care Excellence (NICE), following a partial review of Multiple Technology Appraisal (MTA) TA878.
The final draft guidance recommends nirmatrelvir plus ritonavir as an option for treating COVID-19 in adults for some additional risk groups, namely:
- age 70 years and over
- body mass index (BMI) of 35 kg/m2 or more
- diabetes
- heart failure
The Scottish Medicines Consortium (SMC) has had direct input into the decision-making committee that produced the final draft guidance.
Any amendments to the SMC collaborative advice document will occur following publication of NICE final guidance.
You can read more about the final draft guidance recommendations here: Final draft guidance | Project documents | Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262] | Guidance | NICE
About us
- Who we are
- Horizon scanning
- Public involvement
- Policies & publications
- Minutes
- Meetings
- Register for a meeting
- ILAP
-
Latest update
- HIS website survey
- Speeding up access to new medicines in Scotland: abbreviated process
- International Collaboration
- Joint statement: NICE and SMC/HIS collaboration
- NICE draft recommendations published on the use of treatments for COVID-19
- Healthcare Improvement Scotland
- NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
- Her Majesty Queen Elizabeth II
- April 2022 decisions news release
- New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
- December 2021 decisions news release
- November 2021 decisions news release
- March 2023 decisions news release
- SMC publishes a Collaborative Advice Document for treatments for COVID-19
- Public Partner Advert
- Fast Track Resubmission Process
- NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
- SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
- NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
- SMC publishes Collaborative Advice Documents for ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis.
- Contact us